Daiichi Sankyo presents at an academic conference on the use of a toxicity test database that uses FRONTEO's natural language processing AI technology

　FRONTEO Inc. (Headquarters: Minato-ku, Tokyo; Representative Board of Director and President: Masahiro Morimoto; hereinafter referred to as "FRONTEO") is pleased to announce that at the 2025nd Annual Meeting of the Japanese Society of Toxicology, held from July 7nd to 2th, 4, a research team from Daiichi Sankyo Co., Ltd. (hereinafter referred to as "Daiichi Sankyo") gave an oral presentation entitled "Utilization of Toxicity Test Databases and Their Challenges," in which they reported on their efforts to utilize toxicity test data using FRONTEO's natural language processing AI technology.

　FRONTEO is combining its proprietary specialized AI "KIBIT" (patented in Japan, the US and Europe) with the knowledge of its drug discovery researchers and AI engineers to provide an AI drug discovery support service "Drug Discovery AI FactoryThe presentation introduced Daiichi Sankyo and FRONTEO's efforts to develop a toxicity study database using DDAIF and the analysis of text information in toxicity study reports*.

*Reference: Agreement signed with Daiichi Sankyo regarding optimization and analysis of toxicity information using Drug Discovery AI Factory. Supporting the creation of a groundbreaking discovery AI system that derives new knowledge from toxicity test databases and toxicity test reports (dated November 2024, 11)https://www.fronteo.com/pr/20241112

　In pharmaceutical research and development, it is mandatory to conduct toxicity tests to determine whether or not side effects occur when the drug is administered, and if so, how severe those side effects are. A large amount of useful data is accumulated during toxicity tests, and building a system for collecting and analyzing this data using AI is expected to contribute to the efficient development of safe pharmaceuticals.

　The presentation reported that by constructing and utilizing predictive models using machine learning techniques, it is now possible to efficiently obtain safe compounds, that by comprehensively analyzing in vitro (experiments using cell or tissue models in test tubes or culture vessels) and in vivo (animal experiments using living organisms) non-clinical toxicity test (tests to investigate the efficacy, safety, and toxicity of drug candidate substances prior to clinical trials on humans) data, it is possible to easily confirm the correlation between in vitro and in vivo toxicity, enabling appropriate evaluation of early toxicity test results, and that standardization of data formats has made it easier to conduct analysis across products under development.

　FRONTEO will continue to contribute to the efficient development of safe pharmaceuticals, as well as the business development of its clients, the quality of medical care, and the improvement of patients' quality of life (QOL) through collaboration with researchers and the provision of DDAIF.

About FRONTEO DDAIFURL: https://lifescience.fronteo.com/products/drug-discovery-ai-factory/

"FRONTEO Drug Discovery AI Factory (DDAIF)" is an AI drug discovery support service that combines the knowledge of FRONTEO's drug discovery researchers and AI engineers with "KIBIT" (patented in Japan and the US), an AI specialized in natural language processing. It strongly supports researchers' decision-making in drug development by analyzing disease-related gene networks and building hypotheses about target candidates.
The service has already been introduced at several major pharmaceutical companies and is accumulating a proven track record.

[Reference: Co-creation project with pharmaceutical companies]・ Metagene Therapeutics and FRONTEO begin joint research into microbiome drug discovery, which is attracting worldwide attention. https://www.fronteo.com/pr/20250630・ FRONTEO and Chugai Pharmaceutical launch co-creation project for target discovery using Drug Discovery AI Factory, https://www.fronteo.com/pr/20250515・ EA Pharma and FRONTEO launch co-creation project to explore drug discovery targets using AI, https://www.fronteo.com/pr/20250512・ FRONTEO and Eisai launch co-creation project for target discovery using Drug Discovery AI Factory, https://www.fronteo.com/pr/20250128・ FRONTEO and Maruishi Pharmaceutical launch a co-creation project for biomarker discovery using Drug Discovery AI Factory, https://www.fronteo.com/pr/20250109・ FRONTEO and UBE launch co-creation project on drug repositioning using Drug Discovery AI Factory, https://www.fronteo.com/pr/20241114

[Reference: Joint research projects with academia]・ FRONTEO and Tokyo University of Science begin joint research into discovering new drug discovery targets using the Drug Discovery AI Factory, https://www.fronteo.com/pr/20250513・ FRONTEO and Kumamoto University begin joint research to discover new cancer treatments using Drug Discovery AI Factory, https://www.fronteo.com/pr/20250508

■ About FRONTEO Co., Ltd.　URL: https://www.fronteo.com/FRONTEO supports the judgment of experts in various fields who face social issues day and night through the provision of its proprietary specialized AI "KIBIT," and creates the starting point for innovation. Unlike general-purpose AI, our proprietary natural language processing technology (patented in Japan, the United States, and Europe) enables high-speed and high-precision analysis without relying on the amount of training data or computing power. In addition, by utilizing patented technology that maps (visualizes the structure) the analyzed information, "KIBIT" can directly influence the insights of experts, and in recent years, KIBIT's technology has also been used in hypothesis generation and target discovery in drug discovery.